Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 15, 2025Clinical Lymphoma Myeloma & LeukemiaOpen Access

Rising Unmet Need in Multiple Myeloma Management After First-Line Treatment With DRd: Expected Epidemiological Evolution in Italy

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMario BoccadoroUniversity of Rome Tor VergataRMRiccardo MercatiIQVIA (United Kingdom)CVC VassalloIQVIA (United Kingdom)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Boccadoro et al. (2025) studied this question.

synapsesocial.com/papers/6ab0eae097a3794889ec4f16https://doi.org/10.1016/j.clml.2025.07.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multiple myeloma: patient outcomes in real‐world practice2016 · 329 citations
  2. 2A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab2021 · 90 citations
  3. 3Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data2013 · 555 citations
  4. 4Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis2022 · 7 citations
  5. 5Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment2023 · 17 citations